Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in…

Sanofi to buy Blueprint Medicines for $9.1 bln

Sanofi to buy Blueprint Medicines for $9.1 bln#Sanofi #buy #Blueprint #Medicines #bln

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small…

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III…

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close…

Praxis Precision Medicines to Present at Two February Investor Conferences

Praxis Precision Medicines to Present at Two February Investor Conferences#Praxis #Precision #Medicines #Present #February #Investor #Conferences

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities By Investing.com

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four…

Drugmakers to raise US prices on over 250 medicines starting Jan. 1 By Reuters

By Michael Erman NEW YORK (Reuters) – Drugmakers plan to raise U.S. prices on at least…